Human serum embodies the integrated systemic response to any condition or perturbation, which may regulate muscle protein synthesis (MPS). Conditioning of medium with human serum represents a physiologically relevant method of regulating MPS in vitro. The primary purpose of the study was the development of a model using ex vivo human serum to condition medium and 
INTRODUCTION
Numerous studies have measured muscle protein synthesis (MPS) in vivo using stable isotope tracers of amino acids (AAs) with heavy carbon ( 13 C), deuterium ( 2 H) or nitrogen ( 15 N) motifs. The incorporation of these labelled AAs into muscle protein allows for the calculation of a fractional synthetic rate (FSR) of MPS (Rennie et al., 1982; Yarasheski, Smith, Rennie, & Bier, 1992 ). More recently, 2 H 2 O incorporation techniques have been used to calculate the FSR in more free-living conditions (Wilkinson et al., 2014) . However, these The primary purpose of this study was the development of a new model using ex vivo human serum to condition medium and regulate MPS in in vitro skeletal muscle. In order to achieve this, a number of secondary objectives had to be realized, including the development of an appropriate background medium, preconditioning of muscle cells, and determination of the optimal serum concentration and time course of treatment in which to study MPS. Finally, to demonstrate the functionality of the model, postprandial ex vivo human serum after protein feeding is compared with fasted serum.
METHODS

Ethical approval
The study was approved by the local ethics committee at the University of Limerick (EHSREC_2013_01_13) and conformed to the standards set by the Declaration of Helsinki, except for registration in a database. Four young healthy male participants, (23 ± 3.6 years of age, weighing 75.9 ± 10.1 kg, 1.77 ± 0.06 m tall, with body mass index 24.3 ± 3.3 kg m −2 and 16.4 ± 3.3% body fat) agreed to participate in the study, gave informed written consent and completed the intervention trial.
Study design
Participants reported to the laboratory having fasted overnight (>10 h). A clinical nurse inserted a cannula in the antecubital vein, and a blood sample was collected as baseline (t = 0 min) in S-Monovette R EDTA and S-Monovette R Serum gel tubes (Sarstedt, Wexford, Ireland) . Subsequently, participants consumed 0.33 g (kg body mass) −1 of a whey protein beverage (WP) in 400 ml (7.6%, w/v). Blood samples were collected at 0 min (baseline) and 60 min postprandial. Plasma was used to determine the AA profile and humoral biomarkers, whereas serum was used for cell culture experiments.
Amino acid analysis
The plasma AA profile was determined as previously described using the Agilent 1200 RP-UPLC system (Agilent Technologies Inc., Santa Clara, CA, USA) equipped with an Agilent 1260 binary pump and a G1367C automated liquid handling system (Power-Grant et al., 2016 
Metabolic/humoral biomarker analysis
Plasma glucose concentrations were analysed using a glucose assay Sigma-Aldrich), at 5% CO 2 in a humidified air atmosphere at 37 • C.
At 70% confluence, cells were differentiated in DMEM supplemented with 2% horse serum (H1270; Sigma-Aldrich) as previously described (Murphy, Kiely, Jakeman, Kiely, & Carson, 2016) . Before serum treatment, cells were changed to DMEM AA-and serum-free medium (US biological, Salem, MA, USA) containing 1 mM sodium pyruvate (GE Healthcare, Thermo-Fisher), 1% (v/v) penicillin/streptomycin solution, 1 mM L-glutamine, 6 mM D-glucose (Sigma-Aldrich) and 34 mM NaCl (Sigma-Aldrich) (pH adjusted to 7.3.).
Cell viability
2.6.1 Crystal violet (0, 10, 20, 50 and 100%) 
Muscle protein synthesis
Measurement of MPS using the surface sensing of translation (SUnSET) technique developed by Goodman et al. (2011) was optimized in C2C12 myotubes. After differentiation and maturation (7 days), C2C12 myotubes were nutrient deprived in AA-and serumfree medium for 0.5-4 h to determine the appropriate nutrient deprivation time. Cells were subsequently nutrient deprived for 1 h and treated with human serum (0, 10, 20, 50 or 100%). 
Protein extraction and western blotting
RESULTS
Differentiated myotubes were AA and serum deprived for between 0.5 and 4 h to assess MPS and signalling at different time points of nutrient deprivation. Muscle protein synthesis was reduced within 30 min of nutrient deprivation by ∼80%, and activation of mTOR (∼50%) and P70S6K (∼95%) were significantly reduced within 30 min of nutrient deprivation and remained suppressed for up to 4 h; however, activation of 4EBP1 (∼75%) wss not significantly reduced until 1 h after nutrient deprivation (data not shown). These results suggest that 1 h of nutrient deprivation is sufficient to depress activation of the mTOR signalling pathway and MPS. Based on these findings, subsequent experiments were carried out after 1 h of nutrient deprivation.
Differentiated myotubes were nutrient deprived for 1 h before carrying out cell viability assays for 0.5-4 h using 10-100% pooled fasted human serum obtained from four healthy men (Table 1) . Cell adherence, as measured by the Crystal Violet assay, was significantly reduced after 2 h in 100% serum and after 4 h in 50% serum compared with the control conditions ( Figure 1a ). Cell viability measured by the Real Time MT assay was significantly decreased after 1 h in the 100 and 50% serum conditions compared with control conditions (Figure 1b) .
Treatment of cells with a lower serum concentration (10 or 20%) after 1 h of nutrient deprivation led to no negative effect on cell adherence (all time points; Figure 1a ) or cell viability (all time points; Figure 1b) compared with control conditions. These data provide evidence that treatment with a lower serum concentration (10-20%) has no negative Data represent means ± SD (n = 4). Glucagon-like Peptide-1 (GLP-1); Gastric Inhibitory Polypeptide (GIP).
effects on cell viability during treatment up to 4 h; therefore, the higher serum concentration (20%), which is closer to the in vivo conditions experienced by skeletal muscle, was used for subsequent treatments. Although not statistically significant, a statistical trend was observed for increased activation of mTOR by fed compared with fasted serum (P = 0.06), also with a large effect size (ƞ 2 = 0.59; Figure 3b ). These results demonstrate that ex vivo fed and fasted human serum has the potential to condition medium differentially and regulate MPS mediated by signalling through the mTOR pathway in skeletal muscle cells. Representative western blots of total protein and puromycin incorporation (e) and phosphorylated and total mTOR, P70S6K, 4EBP1 and -actin (f). Abbreviation: Ctl, control. Data are reported as means ± SEM. *P < 0.05, **P < 0.01 and ****P < 0.0001 by one-way ANOVA
DISCUSSION
The primary purpose of this study was the development of a model using ex vivo human serum to condition medium and regulate MPS in in vitro skeletal muscle cells. In order to achieve this, a number of secondary objectives were realized, including the development of an appropriate background medium, the preconditioning of muscle cells, the optimal serum concentration and the time course of treatment in which to study MPS.
A background medium that does not independently stimulate MPS and can be conditioned appropriately to regulate MPS required development. Typically, cells are preconditioned before experimentation with appropriate medium, usually serum free, to synchronize cells and transition to a phase of growth arrest.
Classically, this preconditioning step is ≥4 h in duration. However, information from Ham, Caldow, Lynch, & Koopman (2014) indicated that MPS signalling is switched off within 30 min of removal from growth medium in skeletal muscle. Therefore, we empirically tested the required duration of preconditioning of skeletal muscle cells in appropriate background medium (AA-and serum-free DMEM) to turn off both signalling and MPS. We found that MPS and signalling were sufficiently downregulated within 1 h of preconditioning and adopted this protocol for all subsequent experiments.
To achieve the primary aim of this paper, we needed to establish the appropriate concentration of ex vivo serum to condition medium for treatment of skeletal muscle. Previously, others have used ex vivo human serum in this way for other physiological outcomes, such as myoblast proliferation and metabolic gene expression (Bruckbauer & Zemel, 2011; Nguyen et al., 2014) , using a wide range of serum concentrations (5-25%). Ideally, we wanted to replicate the interstitial concentrations of the key nutrient and hormonal regulators of MPS.
We ( Therefore, a model that could use a serum concentration close to this was desirable. However, cell viability and adherence were negatively affected by high serum concentrations (50-100%) and were thus considered suboptimal (Figure 1a,b) . Cell viability and adherence at 10 and 20% serum were optimal; therefore, the higher serum concentration (20%) was selected for subsequent experimentation.
To develop the measurement of MPS in response to ex vivo human serum treatment, the SUnSET technique was adopted. The time course of treatment with ex vivo human serum and puromycin to observe a measurable effect had to be established. In our hands, we found little evidence of MPS as determined by puromycin incorporation when puromycin was incubated for the last 30 min of treatment as previously described (data not shown; Goodman et al., 2011) . Our data demonstrate that puromycin incorporation is greater when included for the entirety of the treatment (up to 4 h) with ex vivo human serum. (a) (Table 1) might not have been sufficient to distinguish this response. For example, the difference in leucine as a potent stimulator of MPS between fed and fasted serum was ∼200 mol l −1 . At 20% concentration, this difference between fed and fasted is ∼40 mol l −1 . Rennie and colleagues reported that an increase of ∼80 mol l −1 in extracellular leucine is required to increase MPS in vivo (Bohe, Low, Wolfe, & Rennie, 2001; Rennie, 2007) , suggesting that the differences reported here between fed and fasted serum are sufficient to stimulate MPS signalling further but do not result in a statistically measurable difference in MPS. It is also important to note the inter-individual responses evident. For MPS, the fed serum increased MPS relative to fasted serum in only three out of four participants. This impacted the aggregate effect of the group, and is the reason that such a large effect size is not supported by a statistically significant result.
A major strength of this ex vivo-in vitro approach is that human serum reflects the integrated systemic conditions. Therefore, treatment of skeletal muscle with ex vivo serum may be more physiologically relevant and therefore potentially more likely to translate to a human model. Culture medium can be conditioned accordingly to investigate the effects of different conditions, including nutrition, exercise and inflammation. One of the advantages of this approach for nutrient interventions is that the key nutrient regulators that appear in the circulation have undergone human digestion, in contrast to enzymatically simulated gastrointestinal digestion models (PowerGrant et al., 2016) . Furthermore, the humoral factors stimulated by feeding are also present. Therefore, the integrated effect of the nutrient and the physiological response to feeding is captured in the ex vivo serum sample and can elicit a pluripotent effect on MPS in skeletal muscle.
A limitation of the model described here is the concentration of the serum. C2C12 cells do not tolerate exposure to medium conditioned by high concentrations of serum over extended periods (4 h). Although we argue that this is a more physiologically relevant model compared with direct treatment with nutrient formulations or supraphysiological concentrations of key regulators, the interstitial concentrations of key regulators of MPS experienced by the muscle cell in vivo are not reached here (McCormack et al., 2017) . Therefore, the translation of findings from this model to the in vivo conditions is less well known.
Conclusions
In conclusion, in this study we describe the development of a model using ex vivo human serum to condition medium and regulate MPS in in vitro skeletal muscle cells, including the development of an appropriate background medium, the preconditioning of muscle cells, the optimal serum concentration and the time course of treatment in which to study MPS. This study provides proof of principle that ex vivo human serum can be used to condition medium to regulate MPS, mediated by signalling through the mTOR pathway.
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